ReviewFoods (Basel, Switzerland)2026
Recent Advances in the Utilization of Dietary-Derived Exosome-like Nanoparticles in Inflammatory Bowel Diseases.
Review in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Curcumin-Loaded Milk-Derived Exosomes Improve the Developmental Competence of Yak Oocytes by Regulating Mitophagy.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) is a group of chronic autoimmune diseases, including Crohn's disease and ulcerative colitis. The incidence of IBD has been increasing in newly industrialized countries, whereas current conventional therapeutic medications are ineffective and have unavoidable side effects. In recent years, exosome-like nanoparticles (ELNs) isolated from natural dietary ingredients have played a positive role in the treatment of IBD. These vesicles can exert therapeutic effects on IBD through modulating inflammation-related cytokines, repairing the intestinal barrier, and regulating the intestinal microbiota. In this study, we outline the physiological functions and applications of plant-and animal-derived of ELNs in IBD. Particular emphasis is given to the therapeutic mechanism and efficacy of these ELNs Additionally, the modification of ELNs and loading bioactive compounds in ELNs for improved effects on IBD are discussed. Finally, the prospects and challenges of the dietary-derived ELNs are proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.